| 2.85 -0.15 (-5%) | 01-29 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company formerly known as First Wave BioPharma, Inc. (and prior to September 2021, AzurRx BioPharma, Inc.), is dedicated to discovering and advancing localized, non-systemic treatments for various gastrointestinal conditions. Its development pipeline features several key therapeutic candidates: latiglutenase, an oral biotherapeutic formulated to break down gluten into non-immunogenic peptides for celiac disease patients; adrulipase, a recombinant lipase enzyme engineered to facilitate the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist aimed at addressing gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for individuals with inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Furthermore, the company is developing CypCel, a management tool designed to monitor the intestinal health of recovering celiac disease patients. Founded in 2014, the company's operations are based in Boca Raton, Florida.
Fri, 15 May 2026
ENTO Subsidiary Grid AI Announces Letter of Intent with First Hyperscaler AI Data-Center Customer - Wooster Daily Record
Fri, 24 Apr 2026
Entero Therapeutics Stock Jumps After Company Rebrands As GridAI Technologies Corp. - MSN
Fri, 28 Nov 2025
ENTERO THERAPEUTICS INC (ENTO) Stock Chart - ChartMill
Fri, 28 Nov 2025
Entero Therapeutics Stock Jumps After Company Rebrands As GridAI Technologies Corp. - Stocktwits
Fri, 28 Nov 2025
Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX" - The Providence Journal
Fri, 28 Nov 2025
Entero Therapeutics (NASDAQ: ENTO) to Become GridAI, Start Trading as GRDX - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|